Proceed with Caution: Off-label Ketamine Treatment for Major Depressive Disorder
- 777 Downloads
Ketamine offers a promising new option for the treatment of depression, but its increasing off-label use is ethically and clinically inappropriate at the moment.
KeywordsKetamine Depression Ethics Consent Safety
Compliance with Ethics Guidelines
Conflict of Interest
Dominic Sisti and Andrea G. Segal declare that they have no conflict of interest.
Michael Thase reports personal fees from Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Gerson Lehman Group, GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Merck and Co., Neuronetics, Inc., Ortho-McNeil Pharmaceuticals, Pfizer, Roche, Shire US, Inc., Sunovion Pharmaceuticals, Inc., and Takeda. Dr. Thase also has received grants and personal fees from Eli Lilly & Co., Forest Laboratories, and Otsuka as well as royalties from the American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc., and Peloton Advantage.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.••Stix G. From club to clinic: physicians push off-label ketamine as rapid depression treatment, part 1. Scientific American. 2013. This article provides a thorough overview of the current issues and controversies involved in using ketamine as a treatment for major depressive disorder.Google Scholar
- 4.Department of Justice. Intelligence bulletin: ketamine. 2004(2004-L0424-007).Google Scholar
- 5.•Murrough JW, Wan L-B, Iacoviello B, Collins KA, Solon C, Glicksberg B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. 2014;23(3):481–8. doi: 10.1007/s00213-013-3255-x. This study examined neurocognitive performance in depressed patients and found that patients who responded to ketamine 24 h following treatment had poorer baseline neurocognitive performance than nonresponders.CrossRefGoogle Scholar
- 15.Depression Recovery Centers. Prospective Patients. 2014. http://depressionrecoverycenters.com/prospective-patients/.
- 17.••Schatzberg AF. A word to the wise about ketamine. Am J Psychiatr. 2014;171(3):262–4. A review of concerns surrounding the administration of ketamine for major depressive disorder concludes with the argument that until more is known about its effects and risks, “clinicians should be wary about embarking on a slippery ketamine slope.”.CrossRefPubMedGoogle Scholar